Announcements Trials
Browse Landscape

Phase

Phase 2 12Phase 3 5Phase NA 1Phase 1/2 1

Status

Completed 2Active not recruiting 2Terminated 1

Sponsor Class

OTHER 4NETWORK 1

Study Type

Interventional 5

Sponsor

Cancer Type

Plasma cell 5

Conditions

Carcinoma, Non-Small-Cell Lung 156Lung Neoplasms 57Uterine Cervical Neoplasms 53Squamous Cell Carcinoma of Head and Neck 52Nasopharyngeal Carcinoma 51Head and Neck Neoplasms 47Stomach Neoplasms 37Parkinson Disease 4, Autosomal Dominant Lewy Body 35Esophageal Neoplasms 31Urinary Bladder Neoplasms 26Small Cell Lung Carcinoma 21Esophageal Squamous Cell Carcinoma 21Ovarian Neoplasms 19Carcinoma 14Neoplasm Metastasis 13Cholangiocarcinoma 13Recurrence 11Neuroblastoma 11Nasopharyngeal Neoplasms 11Carcinoma, Ovarian Epithelial 11Biliary Tract Neoplasms 11Adenocarcinoma Of Esophagus 11Neoplasms 10Gallbladder Neoplasms 10Carcinoma, Transitional Cell 10Testicular Neoplasms 9Adenocarcinoma of Lung 9Teratoma 8Oropharyngeal Neoplasms 8Endometrial Neoplasms 8

Interventions

Dexamethasone 168Bortezomib 90Lenalidomide 85Thalidomide 44daratumumab 43pomalidomide 42Melphalan 39Cyclophosphamide 33carfilzomib 29Calcium Dobesilate 27Prednisone 19Doxorubicin 16elotuzumab 14Filgrastim 12ixazomib 11isatuximab 11Vincristine 10Peripheral Blood Stem Cell Transplantation 10belantamab mafodotin 9Granulocyte Colony-Stimulating Factor 9Zoledronic Acid 8selinexor 7dexamethasone acetate 7Epoetin Alfa 7Etoposide 6fludarabine 5Cisplatin 5Carmustine 5Radiotherapy 4Mycophenolic Acid 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Phase 3 × Multiple Myeloma × Cisplatin × Clear all
NCT00734877 2026-05-22

TT4B

University of Arkansas

Phase 3 Active not recruiting
382 enrolled
Plasma cell

Multiple Myeloma

NCT00572169 2026-02-05

UARK 2006-66, Total Therapy 3B: An Extension of UARK 2003-33 Total Therapy

University of Arkansas

Phase 3 Active not recruiting
177 enrolled
Plasma cell

Multiple Myeloma

NCT00083915 2017-11-20

DTPACE Followed by Tandem Transplant With Melphalan (MEL) 200 Versus MEL/Dexamethasone/Thalidomide (DT) Platinol/Adriamycin/Etoposide (PACE) Hybrid and DTPACE Consolidation

University of Arkansas

Phase 3 Completed
97 enrolled 7 charts
Plasma cell

Multiple Myeloma

NCT00083551 2015-11-23

UARK 98-026 TT II: Multiple Myeloma Evaluating Anti-Angiogenesis With Thalidomide and Post-Transplant Consolidation Chemotherapy

University of Arkansas

Phase 3 Completed
668 enrolled 7 charts
Plasma cell

Multiple Myeloma, Neoplasms

NCT00005834 2015-03-06

S9922 Combination Chemo Plus Filgrastim With or Without Thalidomide in Refractory Multiple Myeloma

SWOG Cancer Research Network

Phase 3 Terminated
19 enrolled
Plasma cell

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡